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Abstract: Doripenem is a new parental 1-β-methyl carbapenem which, unlike imipenem, 
does not require the addition of cilastatin on administration because of the protection afforded 
to doripenem by the 1-β-methyl component. It combines the in vitro activities of imipenem 
and ertapenem against gram-positive bacteria with the in vitro activity of meropenem against 
gram-negative bacteria. It has excellent bactericidal activity against Streptococcus pneumoniae. 
Carbapenem resistant mutants were selected with less frequency and lower minimum inhibitory 
concentrations (MICs) after exposure to doripenem than to imipenem or meropenem. High 
concentration levels of doripenem may be achieved in plasma. The half life of doripenem is 
higher than imipenem or meropenem. This new antibiotic has excellent in vitro activity and 
pharmacological properties. but how it may best be utilized still needs to be determined. 
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Introduction
Antibiotic resistance is now part of the everyday vocabulary. It is a current problem 
and also one which will not reduce in importance, but rather increase. In order to ensure 
that we can tackle the daily challenges of bacterial infections we need antibiotics. 
However, the march of antibiotic resistance continues and increases with each passing 
year. It is unlikely and unrealistic to think therefore, that we will be able to quell the 
future challenges of antibiotic resistant bacteria with our current dwindling stocks of 
viable antibiotics. Unfortunately, the numbers of new antibiotics produced in the last 
20 years has reduced considerably (Bosso 2005). To optimize the few new emerging 
antibiotics that are developed we must understand where they would best serve our 
needs in the ﬁ  ght against antibiotic resistant bacteria.
Multi-drug-resistant (MDR) bacteria contain many resistance mechanisms 
frequently including mobile resistance genes, which can spread resistance to classes 
of antibiotics within and between bacterial species. Identiﬁ  cation of these bacteria 
and outbreaks caused by these MDR pathogens are increasing in frequency. Some of 
these bacteria, although infrequent to date, have increased their antibiotic resistant 
armory from MDR to pan-resistant, which leaves drug combination as the only viable 
treatment option. It is generally hoped that each new antibiotic launched will be capable 
of effectively inhibiting the increasing number of MDR bacteria, while also causing 
less side effects than those currently associated with antibiotics. This review will 
focus on a new antibiotic, doripenem, which is a member of the carbapenem family 
of antibiotics and will detail the comparative activities of this new antibiotic with a 
view to helping to identify the most effective use of this new antibiotic at a time of 
increasing antibiotic resistance.
Doripenem is a new parental 1-β-methyl carbapenem. The carbapenem class was 
initiated by the development of imipenem in 1985 and expanded by the inclusion of Therapeutics and Clinical Risk Management 2007:3(5) 790
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meropenem in 1996 and most recently by the addition of 
ertapenem. Carbapenem antibiotics are cell wall synthesis 
inhibitors and belong to the β-lactam family of antibiotics. 
Carbapenems differ from most β-lactam antibiotics by hav-
ing stability to AmpC and Extended spectrum β-lactams 
(ESBL). They also do not select AmpC derepressed mutants 
from inducible populations. Doripenem, like meropenem, 
has stability against renal dehydropeptidases, which 
unlike imipenem does not require the addition of cilastatin 
on administration, as a result of the protection afforded by 
the 1-β-methyl component (Mori 1996). Doripenem has 
been developed to date for intravenous use. It has been 
described as having the favorable attributes of both imipe-
nem and meropenem against both gram-positive and gram-
negative bacteria. This review will discuss the published 
data on doripenem to date, which will either concur with 
or oppose this view.
Spectrum of antibiotic comparative 
activities and bactericidal activities
The activity of doripenem compared with other classes of 
antibiotics used widely to treat gram-positive and gram-
negative bacteria has been measured most frequently 
in vitro by comparing the minimum inhibitory concentra-
tions (MIC) of each of these antibiotics. Doripenem was 
second only to imipenem by 1 doubling dilution against 
the oxacillin-susceptible Streptococcus aureus isolates, 
Table 1 (Ge 2004). There was a marked increase in MIC90 
for all carbapenems when tested against the oxacillin-resis-
tant isolates. Oxacillin-resistant S. aureus are resistant to 
all β-lactam antibiotics. Doripenem had excellent activity 
against oxacillin-susceptible coagulase negative S. aureus 
but, as with the other carbapenems, had much reduced activ-
ity against the oxacillin-resistant isolates (Fritsche 2005). The 
MIC90 values of doripenem, imipenem and meropenem were 
the same for penicillin-susceptible and pencillin-resistant 
Streptococcus pneumoniae (Ge 2004). However, the ranking 
order of MIC90 values changed for the penicillin intermedi-
ate isolates to imipenem having the lowest MIC90 followed 
by doripenem, then meropenem and ﬁ  nally ertapenem with 
the highest MIC90. Doripenem activity was equal to that of 
meropenem and imipenem for penicillin susceptible viridans 
Streptococcus but again the order of activity changed for the 
penicillin intermediate isolates; imipenem had the lowest 
MIC90 followed by doripenem and ertapenem with the highest 
MIC90 (Ge 2004; Jones 2004a).
The MIC90 value of doripenem was at least 1 doubling 
dilution lower than the other carbapenems against ceftazidime 
Table 1 Comparative in vitro activity of doripenem
Bacteria Antibiotic  MIC90 values
     (mg/L)
Staphylococcus aureus Doripenem  0.06
Oxacillin susceptible  Imipenem  0.03
 Meropenem  0.12
 Ertapenem  0.25
Staphylococcus aureus Doripenem  32
Oxacillin resistant  Imipenem   32
 Meropenem   32
 Ertapenem   32
Coagulase negative  Doripenem  0.06
Staphylococcus oxacillin  Meropenem  0.12
susceptible Ertapenem  0.5
Coagulase negative  Doripenem  16
Staphylococcus oxacillin  Imipenem  8
 resistant  Meropenem  32
 Ertapene   32
Enterococcus faecalis Doripenem  8
 Imipenem  4
 Meropenem  16
 Ertapenem  16
Enterococcus faecium Doripenem   8
 Imipenem   8
 Meropenem   8
 Ertapenem   8
Streptococcus pneumoniae Doripenem   0.008
Penicillin susceptible  Imipenem   0.008
 Meropenem   0.008
 Ertapenem  <  0.015
Streptococcus pneumoniae Doripenem  0.25
Penicillin intermediate  Imipenem  0.12
 Meropenem  0.5
 Ertapenem  1
Streptococcus pneumoniae Doripenem  1
Penicillin resistant  Imipenem  1
 Meropenem  1
 Ertapenem  2
Viridans Streptococcus Doripenem  0.06
Penicillin susceptible  Imipenem  0.06
 Meropenem  0.06
 Ertapenem  0.25
Viridans Streptococcus Doripenem  0.5
Penicillin intermediate  Imipenem  0.12
 Ertapenem  1
Viridans Streptococcus Doripenem  4
Penicillin resistant  Imipenem  2
 Meropenem  4
 Ertapenem  8
Escherichia coli Doripenem  0.03
ESBL negative  Imipenem  0.5
 Meropenem   0.015
 Ertapenem   0.015
Escherichia coli Doripenem  0.06
ESBL positive  Imipenem  0.5
 Meropenem  0.06
 Ertapenem  0.5
Klebsiella species Doripenem  0.06
ESBL negative  Imipenem   0.5
 Meropenem  0.03
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susceptible or resistant Enterobacter aerogenes and 
Enterobacter cloacae (Ge 2004). Doripenem and meropenem 
had the lowest MIC90s against ESBL producing Escherichia 
coli and Klebsiella isolates (Ge 2004; Fritsche 2005). 
Whereas doripenem had the highest MIC90 for the 1107 
Klebsiella species tested with varying susceptibility proﬁ  les 
(Fritsche 2005). The MIC90s of doripenem, ertapenem and 
meropenem were the same against Aeromonas species tested 
(Fritsche 2005).
Doripenem also had the highest activity against 
Pseudomonas aeruginosa isolated from cystic ﬁ  brosis 
patients or non-cystic ﬁ  brosis patients (Tsuji 1998; Jones 
2004a; Traczewski 2006). Pseudomonas aeruginosa 
isolates from cystic ﬁ  brosis patients are normally more 
mucoid and generally more resistant than their non cystic 
ﬁ  brosis counterparts. It also had the highest activity against 
both carbapenem susceptible and resistant isolates of 
P. aeruginosa (Tsuji 1998; Jones 2004b). Against 24 car-
bapenem, resistant isolates of Acinetobacter baumannii at 
least 12 had doripenem MICs of 8 mg/L or less, the highest 
activity of the 4 carbapenems tested (Jones 2004b). Five 
isolates were susceptible to doripenem, 4 susceptible to 
imipenem and 1 susceptible to meropenem. Therefore, 
doripenem had the ability to be active against the imipenem 
resistance mechanism used by 1 isolate and for 4 isolates 
doripenem superseded the activity of meropenem.
There have been few studies on the bactericidal efﬁ  cacy of 
doripenem. Killing curves have indicated that the Minimum 
Bactericidal Concentration (MBC) of doripenem ranged from 
2-fold to 8-fold greater than the MIC. The bactericidal activity 
of doripenem was observed at 4 X and 8 X MIC for S. aureus, 
Carbapenem resistan  Imipenem  32
 Meropenem  16
Pseudomonas aeruginosa  Doripenem  2
Cystic Fibrosis isolates  Imipenem  16
Burkholderia cepacia Doripenem  8
 Imipenem  8
 Meropenem  4
 Ertapenem  8
Aeromonas Doripenem  1
 Imipenem  2
 Meropenem  1
 Ertapenem  1
Stenotrophomonas maltophilia Doripenem   8
 Imipenem   8
 Meropenem   8
 Ertapenem   8
 Ertapenem   0.06
Klebsiella species Doripenem  0.12
ESBL positive  Imipenem   0.5
 Meropenem  0.12
 Ertapenem  0.5
Klebsiella pneumoniae Doripenem  0.12
ESBL negative  Imipenem  1
 Meropenem  0.03
 Ertapenem   0.015
Klebsiella pneumoniae Doripenem  0.12
ESBL positive  Imipenem  1
 Meropenem  0.06
 Ertapenem  0.25
Enterobacter aerogenes Doripenem  0.12
Ceftazidime susceptible  Imipenem  2
 Meropenem  0.06
 Ertapenem  0.06
Enterobacter aerogenes Doripenem  0.12
Ceftazidime non-susceptible  Imipenem  1
 Meropenem  0.12
 Ertapenem  0.5
Enterobacter cloacae Doripenem  0.06
Ceftazidime susceptible  Imipenem  2
 Meropenem  0.06
 Ertapenem  0.06
Enterobacter cloacae Doripenem  0.25
Ceftazidime non-susceptible  Imipenem  1
 Meropenem  0.25
 Ertapenem  1
Acinetobacter spp Doripenem  4
 Imipenem  2
 Meropenem  8
 Ertapenem   8
Acinetobacter baumannii Doripenem   32
Carbapenem resistant  Imipenem   32
 Meropenem   32
 Ertapenem   32
Acinetobacter baumannii Doripenem  1
Ceftazidime susceptible  Imipenem  0.25
 Meropenem  1
 Ertapenem  8
Acinetobacter baumannii Doripenem   16
Ceftazidime resistant  Imipenem  8
 Meropenem  16
 Ertapenem   16
Citrobacter freundii Doripenem  0.03
Ceftazidime susceptible  Imipenem  1
 Meropenem  0.03
 Ertapenem   0.015
Citrobacter freundii Doripenem  0.12
Ceftazidime non-susceptible  Imipenem  1
 Meropenem  0.06
 Ertapenem  0.5
Pseudomonas aeruginosa Doripenem  0.05
 Imipenem  2
Carbapenem susceptible  Meropenem  1
 Ertapenem  16
Pseudomonas aeruginosat Doripenem  8
Table 1 (Continued)
Bacteria Antibiotic  MIC90 values
     (mg/L)
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E. faecalis, S. pneumoniae, E. coli and K. pneumoniae. The 
results of this study suggested that doripenem killing was as 
frequent at 2X MIC as 8X MIC against S. pneumoniae ATCC 
49619 and thus was time rather than concentration dependent. 
Results for P. aeruginosa showed regrowth of the organism 
at 2X and 4X MIC but not at 8X MIC, which could be due 
to drug inactivation or indicate that bactericidal activity of 
doripenem against P. aeruginosa is not as efﬁ  cient as with 
other bacteria (Jones 2004a). Thus more frequent dosing or 
a higher dose is required for P. aeruginosa infections.
Mutant selection
Transconjugant isolates of E. coli containing OXA, SHV, 
TEM, NMC and IMP resistance β-lactamases were generated 
(Mushtaq 2004a). Doripenem MICs for these isolates were 
comparable to or lower than the other 3 carbapenems; 
meropenem, imipenem and ertapenem and were also similar 
to the MIC against E. coli lacking the plasmid encoded 
resistance genes. Therefore, these resistance mechanisms 
alone do not confer resistance to doripenem. The MIC of 
doripenem was investigated for 2 K. pneumoniae variants of 
a single strain which were IMP positive but lacked an outer 
membrane porin (Mushtaq 2004a). The MIC of doripenem 
for the IMP-1 positive, porin negative isolate was the lowest 
of the 4 carbapenems and was the same as the 4 carbapenems 
for the IMP-1 positive, porin positive variant. However, 
the MICs of the 4 carbapenems were higher for the variant 
without the porin than the variant with the porin, suggesting 
that all 4 carbapenems rely on the same porin to enter the 
bacterial cell, although perhaps to different extents. 
Mutant P. aeruginosa isolates were generated by selection 
on agar containing doripenem (Mushtaq 2004b). The results 
of these experiments elucidated that there were fewer mutants 
produced from exposure to doripenem than the other car-
bapenems and the mutants which were generated had lower 
MICs for doripenem than for the other carbapenems. The 
mutants selected on doripenem, which were non-susceptible 
to doripenem, were co-resistant to the other carbapenems. 
Co-resistance to non-carbapenem β-lactams was observed 
within most multi-step mutants generated from selection with 
doripenem or meropenem, which implies that efﬂ  ux as well 
as loss of the OprD porin has a role in these resistant isolates. 
However, imipenem mainly selected mutants with resistance 
only to carbapenems, which would indicate that resistance 
is due only to loss of the OprD porin. This is worrying as it 
suggests that cross-resistance from doripenem to the other 
carbapenems, especially meropenem, could occur due to ef-
ﬂ  ux upregulation and loss of the OprD porin in the clinical 
setting and vice versa. It is therefore unlikely that doripenem 
would have activity against meropenem resistant isolates.
Doripenem had excellent activity against isogenic strains 
of P. aeruginosa, which contained the OprD porin, regardless 
of AmpC production, in line with all carbapenems (Mushtaq 
2004b). The inﬂ  uence of AmpC only affected the carbapenems 
in isolates lacking the OprD porin. The isolates overexpressing 
AmpC were non-susceptible to the carbapenems but those 
with low level or background levels of AmpC production 
were susceptible to all carbapenems. Therefore, doripenem 
performed in the typical manner of the carbapenems against 
the OprD negative isolates but when the OprD porin was 
present performed at a higher level. This result suggests that 
doripenem enters the bacterial cell at a faster rate than the other 
carbapenems through the OprD porin.
Similar to imipenem and meropenem, doripenem had 
activity against a range of TEM, PSE, PER, NPS and some 
OXA positive isolates of P. aeruginosa (Mushtaq 2004b). 
However, doripenem was weaker against the OXA-10 
high producer isolate. Perhaps the mutation present in this 
OXA-10 enzyme, which differentiates it from the other 
OXA enzymes, enhances the activity of this enzyme to 
target specifically the modified carbapenem structure of 
doripenem. Clinical isolates of P. aeruginosa with various 
VIM and IMP metallo-β-lactamases were resistant to all 
4 carbapenems. However, a Canadian isolate contain-
ing the IMP-7 metallo-β-lactamase was susceptible to 
doripenem only. Perhaps the specific structure or activity 
profile of this enzyme prevents it from interacting with 
the modified carbapenem structure of doripenem. If this 
is the case then doripenem could be used to specifically 
remove or reduce the resistance problem caused by these 
enzymes. The potential is therefore present to produce 
a carbapenem, which has activity against the metallo-β-
lactamases. Further study into which resistance enzymes 
are particularly susceptible to doripenem and how this 
occurs is required. The roles of efflux and the OprD porin 
were not studied in these isolates but could also affect 
susceptibility to certain carbapenems.
Pharmacokinetics, 
pharmacodynamics and in vivo 
efﬁ  cacy
In vivo experiments with doripenem have been performed 
both in mice and rats. Results of the mice experiments 
indicated that doripenem had approximately the same activity 
as imipenem and meropenem or slightly enhanced activity Therapeutics and Clinical Risk Management 2007:3(5) 793
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against S. pneumoniae, S. aureus, E. coli and P. aeruginosa 
(Tsuji 1998). Doripenem also had the advantage of reaching 
high levels in the plasma of mice. In the rat experiments the 
bacteriological activity of doripenem was higher than that of 
imipenem/cilastatin against E. coli and Bacteroides fragilis 
polymicrobial infections (Mikamo 2000).
The MIC values to classify isolates as susceptible and 
resistant to doripenem suggested by Bhavnani et al (2003), 
Thye et al (2003) and Andes et al (2003) are susceptible 
 4 mg/L and resistant  16 mg/L, with intermediate being 
inferred as 8 mg/L. These values were derived by apply-
ing the pharmacokinetic (PK) and pharmacodynamic (PD) 
calculations from Monte Carlo simulations and in vivo 
studies in mice (Bhavnani 2003; Thye 2003; Andes 2003).
The time for which the doripenem concentration exceeds 
the MIC (T   MIC), was found to be the PK-PD that cor-
related best with change in bacterial count (log10CFU/thigh 
mouse) for S. pneumoniae, S. aureus and K. pneumoniae 
(Andes 2003). This model utilized an estimated terminal 
half-life of doripenem of approximately 59.4 minutes based 
on a previous study in human subjects (Bhavnani et al 2005). 
As the range of MICs of doripenem against a diverse range 
of bacterial species is wide, the PK-PD target evaluation was 
found to be best studied within the MIC range of  1 mg/L 
to 2 or 8 mg/L. Using this regimen, in 24 healthy subjects 
between 18 and 65 years of age, Bhavnani et al established 
that by varying the length of doripenem infusion the same 
dosing regimen should allow for the effective treatment of 
pathogens with various MICs with little or no increase in 
drug exposure (Bhavnani 2005). However, due to the few 
studies in this area further research is required before this 
can be recommended. 
Tsuji et al using a mouse model of systemic infection, 
identiﬁ  ed a shorter half-life for doripenem of 17.7 minutes 
(Tsuji 1998). This half life was shorter than imipenem (18.5 
minutes) but longer than meropenem (10.2 minutes). The 
variation in half life times between this study and that of 
Bhavnani et al could be due to the different models used or 
the fact that healthy subjects rather than infected subjects 
were used in the Bhavnani et al study and therefore the 
uptake of drug was less than in the infected mice models. 
The maximum concentration of doripenem achieved in the 
plasma was higher than that achieved by imipenem and 
similar to that of meropenem. 
Conclusion
Many studies detailed in this review identified that 
doripenem had the in vitro activity to match imipenem or 
ertapenem against gram-positive bacteria and meropenem 
against gram-negative bacteria. The bacteria which doripe-
nem had the greatest activity against, compared with other 
carbapenems, were oxacillin-susceptible or resistant S. 
aureus and coagulase negative Staphylococcus, E. faecalis 
and E. faecium, penicillin-susceptible or penicillin-resistant 
S. pneumoniae, viridans Streptococcus, ESBL-producing 
E. coli and Klebsiella species, ceftazidime non-suscep-
tible Enterobacter aerogenes and Enterobacter cloacae, 
Aeromonas, carbapenem-resistant Acinetobacter baumannii 
and P. aeruginosa, carbapenem-susceptible P. aeruginosa 
and P. aeruginosa from cystic ﬁ  brosis patients. This list of 
both gram-positive and gram-negative bacteria demonstrates 
that doripenem has a wide range of activity. However, it 
did not have activity against the ever increasing number of 
metallo-β-lactamase-producing bacteria or those containing 
the plasmid mediated carbapenem-resistant genes. There 
is a great need for an antibiotic with high activity against 
such organisms; doripenem does not appear to be such an 
antibiotic. It also appears that loss of the OprD porin and 
efﬂ  ux may effect the activity of doripenem. 
As doripenem does not require the addition of cilas-
tatin there is decreased seizure potential compared to 
imipenem. The extended dosing interval provides greater 
time above MIC.
The results to date indicate that doripenem is a broad 
spectrum antibiotic which combines the positive qualities of 
both imipenem and meropenem and has slightly enhanced 
activity to both, but it does not out perform these drugs to 
such an extent that either imipenem or meropenem will 
be consigned to the shelf. In its own right doripenem has 
excellent activity but where it ﬁ  ts into the current antibiotic 
prescribing practices still remains to be seen. 
The question, therefore, that remains to be answered is 
the same as those that occurred when new antibiotics from 
other classes were introduced; will this antibiotic improve 
the antibiotic armory currently available to us or will it 
reduce the effectiveness of one of the few remaining effec-
tive classes? The only way we will know the answer to this 
question is to fully understand how resistance will develop to 
doripenem and if doripenem in turn can select for resistance 
to the other members of the carbapenem class. Therefore, 
caution is required in the ﬁ  rst instance until we can answer 
these questions. All early indications show that doripenem 
is an antibiotic that is effective against gram-positive and 
gram-negative bacteria. However, the speciﬁ  c details of 
when and where this antibiotic should be used are still to 
be decided. Therapeutics and Clinical Risk Management 2007:3(5) 794
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